ACP
CLSD

Acuta Capital Partners’s Clearside Biomedical CLSD Stock Holding History

Acuta Capital Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-87,751
Closed -$7.9M – 43
2021
Q3 		$7.9M Hold
87,751
– – 2.79% 10
2021
Q2 		$6.41M Sell
87,751
-19,849
-18% -$922K 2.56% 13
2021
Q1 		$3.99M Buy
107,600
+24,267
+29% +$1.22M 1.44% 30
2020
Q4 		$3.42M Buy
83,333
+42,333
+103% +$1.1M 0.93% 37
2020
Q3 		$947K Buy
+41,000
New +$1.06M 0.26% 42
2017
Q2 		– Sell
-11,667
Closed -$1.39M – 65
2017
Q1 		$1.39M Hold
11,667
– – 0.33% 45
2016
Q4 		$1.56M Buy
+11,667
New +$2.93M 0.58% 29

Other funds holding CLSD

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acuta Capital Partners's CLSD Position: Q4 2021 in Review

Acuta Capital Partners sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 87,751 shares — an estimated $7.9M sold.

Acuta Capital Partners first reported a position in CLSD in Q4 2016 and held it in 7 quarters. The position peaked at $7.9M in Q3 2021. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

  • Acuta Capital Partners reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 87,751 Clearside Biomedical shares in Q4 2021, an estimated $7.9M.
  • Acuta Capital Partners first reported a position in Clearside Biomedical in Q4 2016 and held it in 7 quarters.
  • Acuta Capital Partners's Clearside Biomedical position peaked at $7.9M in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.